Table 1. Baseline Participant Characteristics (n=241).
All characteristics were recorded at the participant’s baseline study visit, conducted from September, 2010 to June, 2013. Continuous variables are presented as median (IQR). Categorical variables are presented as percentages.
| All (n=241) | FSGS (n=95) | MCD (n=62) | MN (n=52) | IgAN (n=32) | |
|---|---|---|---|---|---|
| Age, years | 37 (17, 55) | 36 (17, 52) | 14 (6, 25) | 54 (41, 61) | 42 (32, 54) |
| Female | 90 (37%) | 31 (33%) | 26 (42%) | 20 (38%) | 13 (41%) |
| Black Race | 69 (29%) | 36 (38%) | 21 (34%) | 11 (21%) | 1 (3%) |
| Serum Albumin (g/dL) | 3.1 (2.5, 3.9) | 3.4 (2.4, 4.1) | 3.2 (2.2, 4) | 2.8 (2.3, 3.1) | 3.5 (3.2, 3.8) |
| Total Cholesterol (mg/dL) | 242 (194, 307) | 236 (180, 291) | 227 (192, 311) | 272 (243, 348) | 220 (195, 256) |
| eGFR (mL/min/1.73m2) | 82 (50, 105) | 60 (42, 93) | 104 (86, 126) | 82 (66, 100) | 57 (39, 95) |
| Urine Protein/Creatinine Ratio (mg/mg) | 2.3 (0.8, 4.3) | 2.1 (1.1, 3.9) | 0.5 (0.1, 2.7) | 3.8 (2.5, 7.1) | 2.6 (1.2, 3.3) |
| Plasma suPAR (pg/mL) | 2954 (2360, 3601) | 3178 (2681, 3763) | 2464 (2101, 2973) | 3061 (2668, 3952) | 2974 (2290, 3728) |
| Urine suPAR | 2324 (1742, 3457) | 2135 (1671, 2913) | 2327 (1749, 3457) | 2861 (2013, 4599) | 2128 (1584, 3068) |
| Follow-up Time (months) | 17 (10, 25) | 15 (11, 23) | 17 (8, 24) | 16 (8, 26) | 25 (19, 30) |
| >50% loss of eGFR | 26 (12%) | 14 (16%) | 1 (2%) | 4 (9%) | 7 (23%) |
| ESRD* | 14 (6%) | 6 (7%) | 0 (0%) | 2 (4%) | 6 (19%) |
| Ever Reached Complete or Partial Remission** | 183 (77%) | 65 (70%) | 47 (92%) | 34 (65%) | 27 (84%) |
*
ESRD is defined as initiation of dialysis, receipt of kidney transplant or eGFR<15 mL/min/1.73m2
**
Complete Remission is defined as UPCR<0.3mg/mg. Partial Remission is defined as UPCR decline by 50% from baseline and ≤3.5mg/mg